TG Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	799.54	616.29	329	233.66	2.79	6.69
Revenue Growth	76.08%	87.32%	40.80%	8290.02%	-58.36%	4300.66%
Cost of Revenue	140.94	100.71	38.49	14.13	0.27	0.79
Gross Profit	658.6	515.57	290.52	219.53	2.52	5.9
Selling, General & Admin	296.47	232.03	154.3	122.71	95.48	128.09
Research & Development	225.8	160.22	94.29	76.19	125.35	222.58
Operating Expenses	522.27	392.25	248.59	198.9	220.84	350.67
Operating Income	136.33	123.32	41.93	20.63	-218.32	-344.77
Interest Expense	-37.49	-26.73	-24.03	-12.62	-10.19	-5.64
Other Non Operating Income (Expenses)	11.92	10.79	7.69	5.04	4.7	2.31
Pretax Income	101.6	107.39	25.59	13.06	-223.81	-348.1
Income Tax Expense	-339.89	-339.79	2.21	0.39	-	-
Net Income	441.49	447.18	23.38	12.67	-223.81	-348.1
Net Income to Common	441.49	447.18	23.38	12.67	-223.81	-348.1
Net Income Growth	630.24%	1812.41%	84.52%	-	-	-
Shares Outstanding (Basic)	143	144	145	142	135	132
Shares Outstanding (Diluted)	159	161	160	149	135	132
Shares Change	-5.56%	0.67%	7.96%	9.67%	2.41%	14.64%
EPS (Basic)	3.10	3.10	0.16	0.09	-1.65	-2.63
EPS (Diluted)	2.77	2.77	0.15	0.09	-1.65	-2.63
EPS Growth	667.52%	1746.67%	68.03%	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	17.39	-24.99	-40.56	-31.41	-176.18	-296.04
Free Cash Flow Per Share	0.11	-0.15	-0.25	-0.21	-1.30	-2.24
Gross Margin	82.37%	83.66%	88.30%	93.95%	90.48%	88.19%
Operating Margin	17.05%	20.01%	12.74%	8.83%	-7838.99%	-5154.28%
Profit Margin	55.22%	72.56%	7.11%	5.42%	-8036.34%	-5204.08%
Free Cash Flow Margin	2.17%	-4.05%	-12.33%	-13.44%	-6326.18%	-4425.70%
EBITDA	136.45	123.38	42	20.84	-218.01	-344.49
EBITDA Margin	17.07%	20.02%	12.77%	8.92%	-	-
D&A For EBITDA	0.12	0.06	0.07	0.21	0.3	0.28
EBIT	136.33	123.32	41.93	20.63	-218.32	-344.77
EBIT Margin	17.05%	20.01%	12.74%	8.83%	-	-
Effective Tax Rate	-	-	8.64%	2.99%	-	-
Revenue as Reported	799.54	616.29	329	233.66	2.79	6.69

SEC Filings: 10-K · 10-Q